NeoGenomics Inc (NEO)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 14.11 | 15.15 | 15.82 | 17.66 | 14.37 | 14.18 | 13.28 | 13.31 | 13.26 | 13.46 | 14.39 | 12.68 | 12.71 | 13.07 | 13.22 | 12.76 | 8.76 | 11.96 | 10.61 | 11.00 |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 2.24 | 2.19 | 2.14 | 1.23 | 1.18 | 1.16 | 1.13 | 1.06 | 0.99 | 0.96 | 0.91 | 0.85 | 0.81 | 0.79 | 0.78 | 0.52 | 1.18 | 1.19 | 1.13 | 2.84 |
NeoGenomics Inc's inventory turnover ratio has generally been increasing over the past few years, indicating that the company is selling its inventory more efficiently. This suggests that NeoGenomics is managing its inventory well and turning it into sales at a faster rate.
The lack of data for receivables turnover and payables turnover ratios makes it difficult to assess the efficiency of the company in collecting receivables and paying its payables within a specific period.
In terms of working capital turnover, the ratio shows a fluctuating trend over the years. Generally, a higher working capital turnover ratio indicates that the company is generating more revenue per dollar of working capital. NeoGenomics' working capital turnover has shown an upward trend in recent years, suggesting improvements in utilizing its working capital to generate sales.
Overall, based on the activity ratios analyzed, NeoGenomics appears to be efficiently managing its inventory and working capital, but without information on receivables and payables turnover, a comprehensive assessment of the company's overall efficiency in managing its assets and liabilities cannot be made.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 25.87 | 24.09 | 23.07 | 20.67 | 25.41 | 25.75 | 27.49 | 27.41 | 27.53 | 27.11 | 25.36 | 28.79 | 28.73 | 27.93 | 27.62 | 28.60 | 41.68 | 30.51 | 34.41 | 33.17 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
NeoGenomics Inc's Days of Inventory on Hand (DOH) has shown a decreasing trend from 33.17 days on March 31, 2020, to 25.87 days on December 31, 2024. This indicates the number of days it takes for the company to sell its inventory has been declining gradually over the years, which generally signifies efficient inventory management.
The Days of Sales Outstanding (DSO) and the Number of Days of Payables are not available in the provided data, so we are unable to assess the efficiency of the company in collecting receivables and paying its liabilities within the industry standards and its own credit terms.
In conclusion, while NeoGenomics Inc has shown improvements in its inventory management efficiency as indicated by the decreasing trend in Days of Inventory on Hand, further information on Days of Sales Outstanding and Number of Days of Payables is necessary to provide a more comprehensive analysis of the company's activity ratios.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | — | — | — | — | 5.51 | 5.15 | 4.97 | 4.65 | 2.32 | 2.30 | 2.29 | 4.52 | 2.93 | 4.81 | 5.18 | 4.98 | 4.82 | 5.03 |
| Total asset turnover | 0.40 | 0.39 | 0.38 | 0.37 | 0.35 | 0.34 | 0.33 | 0.31 | 0.29 | 0.28 | 0.27 | 0.27 | 0.26 | 0.25 | 0.26 | 0.30 | 0.45 | 0.44 | 0.43 | 0.57 |
The Fixed Asset Turnover ratio of NeoGenomics Inc indicates the company's efficiency in generating sales revenue from its fixed assets. From March 2020 to December 2024, the ratio fluctuated, with a peak of 5.51 in June 2023. The ratio experienced a significant decline from June 2021 to March 2022, reflecting potential inefficiencies in utilizing fixed assets. However, the ratio showed signs of improvement, reaching 4.97 in December 2022 and remaining relatively stable above 4 in subsequent periods.
The Total Asset Turnover ratio measures the company's ability to generate sales from all its assets. NeoGenomics Inc's ratio ranged from 0.26 in June 2021 to 0.40 in December 2024. The ratio showed a general upward trend over the period, indicating enhanced asset utilization over time. This improvement suggests that the company is becoming more efficient in generating sales in relation to its total assets.
Overall, the analysis of both Fixed Asset Turnover and Total Asset Turnover ratios demonstrates NeoGenomics Inc's progress in optimizing its asset utilization and generating sales revenue efficiently over the examined period. These ratios provide valuable insights into the company's operational performance and efficiency in managing its asset base.